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Background: The previous investigation demonstrated the radioprotective efficacy of peptides isolated from the
venom of Buthus Martti Karsch. In this study, the effect of isolated scorpion venom peptide II (SVPII) on irradiated
M-NFS-60 cells and mouse bone marrow mononuclear cells (BM-MNCs) was observed. The AlamarBlue cell viability
assay, a colony-forming unit (CFU) assay, flow cytometry (FCM), immunofluorescence, and Western blotting were
used to evaluate cell proliferation, cell cycle progression, and the expression of the IL-3 receptor (IL-3R) protein in
non-irradiated and irradiated cells.
Results: Proliferation of irradiated M-NFS-60 cells was significantly accelerated by SPVII, and this effect was further
enhanced by co-application of IL-3. Similarly, SPVII increased the number of BM-MNC CFUs and this proliferative
effect was greater in the presence of SVPII plus IL-3. In addition, SPVII significantly altered cell cycle progression;
SVPII enhanced the fraction of unirradiated M-NFS-60 cells in S phase and the fraction of irradiated M-NFS-60 cells
arrested in G2/M. The expression of IL-3R protein by unirradiated M-NFS-60 cells was enhanced significantly by
SVPII, and SVPII-induced IL-3R overexpression was 10-fold greater in irradiated M-NFS-60 cells.
Conclusions: These results indicated the hematopoietic growth factor (HGF)-like effects of SVPII on irradiated cells,
possibly mediated by upregulation of IL-3R.
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Irradiation therapy serves as one of the main treatments
for malignant carcinoma. Radiotherapy kills cancer
cells, but also injures actively proliferating healthy cells.
Bone marrow is among the most vulnerable tissues to
radiotherapy-induced damage. Irradiation may lead to
hematopoietic failure, significantly decreasing the effi-
cacy of cancer treatment and negatively impacting pa-
tient quality of life. The recovery of hematopoiesis relies
on the proliferation and differentiation of undamaged
hematopoietic stem cells (HSCs) under the regulation of
a specific group of cytokines. Hence, recombinant cyto-
kine treatment is the traditional therapy for mitigating* Correspondence: tianhankong@163.com; dong_gz@163.com
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reproduction in any medium, provided the orthe inhibitory effect of irradiation on hematopoiesis [1].
The most common drugs used to reverse hematopoietic
suppression are colony stimulating factors (CFSs), includ-
ing granulocyte CSF (G-CSF), granulocyte-macrophage
CSF (GM-CSF) [2], and monocyte-macrophage CSF (M-
CSF). However, the efficacy of these CSFs is limited and
cytokine treatment also causes additional adverse events
[3,4].
Agents that confer radiation-resistance have been studied
for over 40 years. Thousands of potential agents have been
investigated, including sulfur compounds and vitamins [5],
plant-derived drugs [6,7] and cytokines [8]. However, most
of these agents are unable to satisfy the requirements of ef-
fectiveness, low toxicity and specificity. Our previous re-
search indicated that scorpion venom peptides (SVPs)
protected against radiation-induced bone marrow injury,
accelerated the formation of hematopoietic cell colonies. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SVPII and SVPIII enhanced proliferation of irradiated
M-NFS-60 cells (applied alone or with IL-3). M-NFS-60 cells were
irradiated for 5 min (5 Gy total dose) and then treated with PBS (control),
3 mg/L SVPII for 48 h (II), 3 mg/ml SVPIII for 48 h (III), 10 μg/L IL-3 for 48
h (IL-3), or the indicated combinations (II + IL-3, III + IL-3). *P < 0.01 vs.
control; #P < 0.05 vs. II or vs. III).
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cytokines in bone marrow and blood, resulting in en-
hanced recovery of hematopoiesis in irradiated mice
[9-11]. Based on the outcomes of our preliminary investi-
gation, the proliferation accelerating effect and mecha-
nisms of SVPs on the cytokine-dependent M-NFS-60 cell
line (ATCC: CRL-1838™), un-irradiated or irradiated, and
primary mouse bone marrow mononuclear cells (BM-
MNCs) were observed.
The proliferation of M-NFS-60 cells depends on both
M-CSF and IL-3. Under cytokine treatment, M-NFS-60
cells rapidly proliferate but maintain the characteristics of
immature bone marrow cells [12]. Therefore, M-NFS-60
cells are commonly used for studies on hematopoiesis. IL-
3 promotes pleuripotent hematopoiesis by stimulating the
self-renewal of early pleuripotent stem cells and the prolif-
eration and differentiation of marrow-derived progenitor
cells, resulting in the continued production and survival of
mature blood cells [13,14]. Previous studies confirmed that
IL-3 can protect bone marrow cells against radiation-
induced apoptosis and regulate the expression of certain
oncogenes such as c-myc. In addition, IL-3 protects bone
marrow cells against DNA damaging agents [15]. In this
study, M-NFS-60 and BM-MNCs cells were treated with
either SVPII alone or in combination with IL-3. SVPII pro-
moted the proliferation of irradiated M-NFS-60 cells and
stimulated the colony formation of non-irradiated bone
marrow cells. These effects were further increased when
SVPII was combined with IL-3. Furthermore, SVPII signifi-
cantly altered M-NFS-60 cells cycle progression, increasing
the fraction of unirradiated cells in S phase and irradiated
cells in G2/M. In addition, SVPII upregulated the expres-
sion of the IL-3 receptor (IL-3R), especially following ir-
radiation, suggesting that the proliferation accelerating
effect of SVPII on irradiated cells depends on activation of
IL-3R-mediated signaling pathways.
Results
Effect of SVP on the proliferation of irradiation or non-
irradiation M-NFS-60 cells
The proliferation of non-irradiated M-NFS-60 cells was
markedly enhanced by treatment with scorpion venom
proteins SVPII and SVPIII (1–3 mg/L for 24 or 48 h). Pro-
liferation was greater at 3 mg/L than at 4 mg/L (data not
show), so all subsequent experiments were conducted
using the optimal concentration range of 1–3 mg/L. The
proliferation of irradiated M-NFS-60 cells was accelerated
by SVPII and SVPIII (3 mg/L for 48 h) as revealed by the
AlamarBlue cell viability assay (P < 0.01; Figure 1). Prolif-
eration was also enhanced by IL-3 alone (10 μg/L for 48
h). The combination of SVP (SVPII or SVPIII at 3 mg/L)
plus IL-3 for 48 h exerted the greatest effect on cell prolif-
eration (P < 0.01 vs. control; P < 0.05 vs. SVP alone;
Figure 1).Thus, both SVPs and IL-3 promoted the proliferation
of irradiated M-NFS-60 cells and the effect of combined
SVP + IL-3 treatment was more obvious. As SVPII + IL-3
exerted a larger proliferative effect than SVPIII + IL-3,
SVPII was used in all the subsequent experiments.Effect of SVP on mouse hematopoietic cell CFU count
BM-MNCs were isolated from BALB/C mice and
used to examine the effect of SVPII on primary
hematopoietic cell proliferation and survival. Isolated
BM-MNCs were cultured for up to 14 days in methyl
cellulose medium with SVPII (1 mg/L or 3 mg/L) or
SVPll plus the cytokines IL-3 (10 μg/L) and rhM-CSF
(62 μg/L). Treatment with SVPII alone increased the
CFU count; the CFU count in 1 mg/L SVPII alone
peaked on the 7th day after administration and then
declined (P < 0.05 on day 7 vs. controls), while the
CFU count in 3 mg/L SVPII was higher on the 11th
and 14th day compared to the 7th day and signifi-
cantly greater than PBS-treated controls on all meas-
urement days (P < 0.05) (Table 1, Figure 2). The CFU
number in cytokine-treated groups peaked on day 7
and remained significantly higher than controls on all
subsequent days (P < 0.05). At all measured time
points, the CFUs were higher in the 1 mg/L SVPII +
cytokines group and the 3 mg/L SVPII + cytokine
group compared to all other treatment groups, con-
sistent with the synergistic effect of SPVII plus cyto-
kines observed in M-NFS-60 cells. The CFU count in
the 1 mg/L SVPII + cytokines group peaked on the
7th day (P < 0.05) and then declined, while the CFU
count in the 3 mg/L SVPII + cytokines group was
higher on the 11th and 14th day compared to day 7
and significantly higher than all other groups on day
14 (P < 0.05).
Table 1 The effect of SVPII on the CFU of BALB/C mouse
BM-MNCs (x ̅ ± s)
Groups 7d 11d 14d
Control 69.50 ± 11.50 51.23 ± 8.76 29.00 ± 4.56
Cytokines 225.47 ± 14.24* 107.50 ± 22.74* 87.23 ± 16.38*
SVPII 1mg 197.50 ± 11.50* 62.50 ± 6.02 46.58 ± 6.78




424.5 ± 32.74*#‡△ 231.00 ± 18.62*#‡△ 214.00 ± 15.37*#‡
SVPII 3 mg
+ Cytokines
315.50 ± 23.33*#‡△ 286.50 ± 21.36*#△‡ 305.47 ± 13.69*#‡△
*P < 0.05 vs. control; #P < 0.05 vs. cytokine treated; ‡P < 0.05 vs. 1 mg/L SVPII;
△P<0.05 vs. 3 mg/L SVPII.
Table 2 Effect of SVPII on M-NFS-60 cell cycle progression
(24 h; % of total cells)
Group G0-G1 G2-M S
24 h Control 40.02 ± 5.25* 2.68 ± 4.58 56.76 ± 1.09*
Serum-free control 57.17 ± 1.66 2.67 ± 3.73 39.88 ± 1.95
SVPII 3 mg/L 39.92 ± 2.15* 2.17 ± 3.45 57.98 ± 5.68*
IL-3 10 μg/L 45.41 ± 3.63* 1.14 ± 1.67 53.13 ± 5.01*
The 24 h control cells were incubated in media containing 10% FCS + 62 μg/L
rhM-CSF. All other cultures were treated with media plus rhM-CSF but without
serum (serum-free media) or incubated in this same media supplemented with
SVPII or IL-3 for 24 h. * P < 0.05 vs. serum-free control.
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As shown in Tables 2 and 3, SVPII promoted the prolif-
eration of M-NFS-60 cells under serum-free conditions
as evidenced by an increase in the total number of cells
in S phase (P < 0.05 vs. serum-free controls) after bothFigure 2 Effect of SVPII on CFU count on 11th and 14th days in vitro
were treated by: A: PBS (Control), B: cytokines (10 μg/L IL-3 and 62 μg/L rhM-C
SVPII + cytokines. Treated BM-MNCs were added into methyl cellulose half-solid24 h and 96 h treatment. In fact, the fraction of cells in
S phase was significantly higher in M-NFS-60 cultures
treated for 96 h with SVPII than in cultures treated for
96 h with IL-3 (Table 3).
After irradiation by 60Coγ-ray, M-NFS-60 cells were
incubated in culture medium containing 10% FCS, 15.5
μg/L rhM-CSF (25% of the normal dose), and 3 mg/L
SVPII for 48 h and cell cycle progression compared to(magnification: ×100). BM-MNCs (1 × 106 cells/mL) of BALB/C mouse
SF), C: 1 mg/L SVPII, D: 3 mg/L SVPII, E: 1 mg/L SVPII + cytokines, F: 3 mg/L
medium and CFU was count on the 11th and 14th days.
Table 3 Effect of SVPII on M-NFS-60 cell cycle progression
(96 h; % of total cells)
Group G0-G1 G2-M S
96 h Control 45.51 ± 13.52 8.51 ± 2.95 41.97 ± 16.47
Serum-free control 71.56 ± 5.60 8.16 ± 5.10 20.29 ± 10.71
SVPII 3 mg/L 41.22 ± 14.96 * 4.29 ± 2.70 54.47 ± 17.66 *
IL-3 10 μg/L 51.81 ± 18.23 3.11 ± 1.40 44.88 ± 19.87
Cells were incubated in media containing 10% FCS + 62 μg/L rhM-CSF for 96 h
(96 h control). All other cultures were treated with media plus rhM-CSF but
without serum for 24 h and then treated for an additional 72 h with media
supplemented with 10% FCS + 62 μg/L rhM-CSF (serum-free control) or treated
with SVPII 3 mg/L or IL-3 10 μg/L in the same media. * P < 0.05 vs.
serum-free control.
Figure 3 Influence of SVPII on IL-3 receptor expression in
M-NFS-60 cells (% IL-3R + cells). Control: cells treated with solvent
(PBS); II: cells treated with 3 mg/L SVP II; IL-3: cells treated with 10
μg/L IL-3; II + IL-3: cells treated with 3 mg/L SVP II and 10 μg/L IL-3
simultaneously. *P < 0.05 vs. control group.
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radiated cells treated with 10 μg/L IL-3 (Table 4).
After irradiation and 48 h incubation in media with
25% rhM-CSF (15.5 μg/L), 32.21% of M-NFS-60 cells
were in S phase and 31.71% were in G2-M phase. For ir-
radiated cells treated with IL-3 for 48 h, the proportion
of cells in G2-M phase was significantly higher (65.38%),
as were the percentage of apoptotic cells (31.95%). For
the irradiated cells treated with SVPII for 48 h, 46.27%
were arrested at G2-M phase, significantly higher than
in irradiated group (drug-free). However, the percentage
of cells in S phase was significantly decreased and the
fraction of apoptotic cells was lower than in the IL-3
treatment group.
Effect of SVP on the expression of IL-3R
Effect of SVP on the expression of IL-3R in M-NFS-60 cells
Following 48 h SVPII treatment, the expression level of IL-
3R in M-NFS-60 cells was detected by FCM and cell
immunoflurorescence. Flow cytometry indicated that the
expression of IL-3R was upregulated after SVPII treatment
and further enahanced by SVPII plus IL-3 (Figure 3). Im-
munofluorescence yielded similar results (Figure 4). The
highest fluorescence intensity was observed in the SVPII +
IL-3 group, followed by the IL-3 group, SVPII group, and
normal controls (lowest), suggesting that the enhancement
of M-NFS-60 cell proliferation by SVP may be associated
with upregulation of IL-3R.Table 4 Effect of SVPII on irradiated M-NFS-60 cell cycle
progression (% of total cells)
Group G0-G1 G2-M S Apoptosis
Control 40.16 ± 3.40 6.69 ± 0.70 52.86 ± 4.83 0.01 ± 0.00
Irradiated 34.45 ± 1.75 31.71 ± 3.16 32.21 ± 2.65 15.81 ± 1.26
IL-310
μg/L
14.72 ± 0.91* 65.38 ± 5.11* 20.93 ± 2.76* 31.95 ± 4.11*
SVPII 3
mg/L
36.65 ± 2.07# 46.27 ± 4.28*# 16.92 ± 1.95*# 21.09 ± 2.05*#
Cells were unirradiated (Control), irradiated and then incubated for 48 h in
media with 25% rhM-CSF (15.5 μg/L) for 48 h(Irradiated), or irradiated and then
treated with 15.5 μg/L rhM-CSF + IL-3(IL-310 μg/L) or 15.5 μg/L rhM-CSF + SVPII
(SVPII 3 mg/L). * P < 0.05 vs. irradiated group; #P < 0.05 vs. IL-310 μg/L group.The growth of M-NFS-60 cells depends on the cytokine
M-CSF. As the expression of IL-3R will be induced by M-
CSF, IL-3R expression in response to IL-3 or SVPII was
measured at normal M-CSF dose (62.5 μg/L) and 25% of
the normal M-CSF dose (15.5 μg/L). Western blotting re-
sults revealed that SVPII significantly upregulated the ex-
pression of IL-3R at both M-CSF doses, while SPVII plus
IL-3 exhibited a strengthening effect on IL-3R expression
(Figure 5).
Effect of SVP on the expression of IL-3R in irradiated
M-NFS-60 cells
Westerm blot and immunofluorescence results strongly
suggested an association between the proliferation-
promoting effect of SVPII (and SVPII plus IL-3) and
upregulated expression of IL-3R, at least in unirradiated
M-NFS-60 cells. In irradiated M-NFS-60 cells, the expres-
sion level of IL-3R was also significantly upregulated by
48 h of SVPII treatment and further enhanced by combin-
ing SVPII and IL-3 (Figure 6). Indeed, expression was ap-
proximately 10-fold higher than in SVPII- or SVPII +
IL-3-treated unirradiated cells, underscoring the pos-
sible role of IL-3R overexpression in SVPII-mediated
hematopoietic cell proliferation after radiation.
Discussion
Hematopoietic injury is a common and severe compli-
cation of radiation treatment for malignant carcinoma,
and can lead to anemia, infection, and hemorrhage.
Cytokines serve as one of the most effective drugs for
the treatment of hematopoietic dysfunction. However,
irradiated hematopoietic cells exhibit a decreased pro-
liferative response toward cytokines. Furthermore,
Figure 4 Immunofluorescence images demonstrating the influence of SVPII on IL-3 R expression by M-NFS-60 cells (×200). A. Control:
cells treated with solvent (PBS); B. IL-3: cells treated with 10 μg/L IL-3; C. SVPII: cells treated with 3 mg/L SVP II; D. SVPII+IL-3: cells treated with 3
mg/L SVP II and 10 μg/L IL-3 simultaneously.
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the recovery of hematopoiesis, increasing the risk of
adverse events and the patients’ financial burden [3,4].
Seeking an efficacious irradiation-resistance agent that
promotes hematopoiesis with less severe adverse events
could greatly improve the therapeutic efficacy of radiation
treatment for malignant carcinoma patients.Figure 5 Influence of SVPII on IL-3R expression by M-NFS-60
cells. A. Normal culture condition: 10%FCM + rhM-CSF 62 μg/L);
B. Low concentration of M-CSF: 10%FCM+ rhM-CSF 15.5 μg/L; 1.
Control: cells treated with solvent(PBS); 2. IL-3: cells treated with 10
μg/L IL-3; 3.SVPII: cells treated with 3 mg/L SVP II; 4. SVPII + IL-3: cells
treated with 3 mg/L SVP II and 10 μg/L IL-3 simultaneously.Preliminary studies indicated that the peptide isolated
from Buthus martensii scorpion venom could inhibited the
growth of H22 tumor. When the venom peptide was admin-
istered simultaneously with radiation, the inhibiting effect
on H22 was enhanced and radiation injury on H22-bearing
mice could be antagonized by peptide too [9]. The further
study showed that SVPs stimulated the secretion of multiple
cytokines (IL-1 α, SCF, IL-6, and GM-CSF) in irradiated
mice and increased the count of peripheral leucocytes, bone
marrow karyocytes, and the number of CFUs formed by iso-
lated bone marrow cells [10,11]. These results suggested that
scorpion venom peptides possess the effect of radiation in-
jury mitigation and tumor suppression. At present study we
choose M-NFS-60 cells, which were routinely and widely
used for modeling hematopoietic events, as the target cells.
Our study demonstrated that the isolated peptides SVPII en-
hanced the proliferation of M-NFS-60 cells, especially after
irradiation. The CFU count of bone marrow cells from
BALB/C mice was significantly increased after 7, 11, and 14
days of SVPII treatment. This effect was further enhanced
when SVP was combined with IL-3.
The reversal of radiation-induced hematopoietic sup-
pression relies on the survival of hematopoietic stem/
progenitor cells and reactivated proliferation and differ-
entiation. A variety of cytokines are required during the
Figure 6 Influence of SVPII on IL-3 R expression of M-NFS-60
cells after irradiation (% IL-3R + cells). After irradiated, the cells
were treated with solvent(control) or 3 mg/L SVP II(II) or 10 μg/L IL-3
(IL-3) or with 3 mg/L SVP II and 10 μg/L IL-3 simultaneously(II + IL-3).
*P < 0.05 vs. control.
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multiple cytokine therapy at advanced-stages of radiation-
induced hematopoietic suppression exerted no restorative
effect [16]. Hérodin F et al. found that many cytokines, in-
cluding SCF, FLT-3, TPO, IL-3, and SDF-1 can protect ani-
mals from irradiation when administered before the onset
of severe damage [16]. Thus, short- and long-term survival
after irradiation depends on timely treatment with the ap-
propriate combination of cytokines at optimal concentra-
tions. We observed an enhancing efficacy of SVPII and
IL-3 on proliferation in both irradiated and unirradiated
M-NFS-60 cells, suggesting that SVPII possesses cytokine-
like functions. This combination cytokine therapy not only
stimulated cell proliferation, but enabled surviving cells to
enter the cell cycle after irradiation. Seven days after irradi-
ation, 35% of cells were arrested in S phase. By contrast, a
previous study found that 80% of irradiated cells not
treated with IL-3 and stem cell factor failed to enter the
cell cycle and a significant fraction became apoptotic
[17], indicating that cytokines enhance the recovery of
hematopoiesis after irradiation possibly by promoting
cell cycle re-entry of HSCs and/or hematopoietic pro-
genitor cells (HPCs). In the current study, the propor-
tion of M-NFS-60 cells at S phase was significantly
increased after 24 h of SVPII treatment under serum-
free conditions, and the number of cells in S phase was
even greater after 96 h treatment. This prolonged SVPII
treatment induced more M-NFS-60 cells to enter S
phase than IL-3 treatment alone.
Cell cycle arrest and apoptosis are the major mechanisms
of radiation-induced bone marrow damage. Damage to
DNA activates cell cycle checkpoint proteins and cell
cycle arrest at G1 or G2. BAF3 cells resisted X-ray- andcytotoxin-induced injury when the culture media was
supplemented with IL-3. Treatment with IL-3 exerted
no apparent effect on early-stage DNA damage and re-
pair, but played an essential role in preventing the ac-
celeration of DNA fragmentation at the G2 phase block
point [15]. In addition, IL-3 can accelerate G2/M phase ar-
rest and prevent apoptosis of mouse hematopoietic pro-
genitor 32D and human UT7 cell lines in response to
etoposide, a type II topoisomerase inhibitor [18]. We
found that the proportion of IL-3-treated M-NFS-60 cells
arrested at G2/M phase was 65.38%, significantly higher
than the 31.71% measured in the control group after ir-
radiation, while the percentage of apoptotic cells (31.95%)
was higher than in the control group (15.81%). Gottlieb E
et al. [19] observed that IL-3 prevented the apoptosis of
DA-1 lymphoma cells at a low irradiation dose. However,
p53-dependent DA-1 cell apoptosis occurred at a higher
radiation dose even in the presence of IL-3. In our investi-
gation, the relatively high radiation dose used may have
overcome the effect of IL-3 so that apoptosis still oc-
curred. However, the number of apoptotic M-NFS-60 cells
after SVPII treatment was not significantly different from
the irradiated control group. In addition, SVPII had a
regulatory effect on cell cycle progression similar to IL-3,
significantly increasing the proportion of cells at G2-M
phase (to 46.27%) and decreasing the number of cells at S
phase. Thus, SVPII has advantages over IL-3 for
protecting M-NFS-60 cells in response to a relatively
high radiation dose. SVP II may prevent DNA fragmen-
tation and apoptosis at G2 checkpoints after irradi-
ation, although additional studies are necessary to test
this possibility.
SVPII promoted the proliferation of IL-3-dependent M-
NFS-60 cells, while the combined application of SVPII and
IL-3 strengthened the proliferation-promoting effect of ei-
ther agent alone, suggesting that activation of IL-3R path-
ways may have contributed to the enhanced proliferation of
M-NFS-60 cells. Whether the effects of SVPII and IL-3 were
functioned via IL-3Rs was studied by measuring IL-3R ex-
pression in M-NFS-60 cells. Both FCM and immunofluores-
cence results indicated that the expression level of IL-3R
was upregulated in M-NFS-60 cells after SVPII treatment. A
greater increase in IL-3R expression was measured when
M-NFS-60 cells were treated with both SVPII and IL-3, and
this enhanced expression was observed under both normal
M-CSF and low (25%) M-CSF concentrations. Western
blotting also indicated that SVPII significantly upregulated
the expression of IL-3R, and exhibited a strengthening ef-
fect with IL-3, indicating that the proliferation-enhancing
effect of SVPII on M-NFS-60 cells is likely due to IL-3R
upregulation. The mutated fibroblast cytokine receptor
F36VFGFR1 facilitated the expansion of HSCs in vivo and
in vitro, while F36VMpl, a mutant thromboietin receptor,
promoted the recovery of myeloid hematopoiesis after
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hematopoiesis [20]. Monzen S et al. [21] recently reported
that the cytokine receptor genes KIT and IL-3R, as well as
genes related to early hematopoiesis and oxidation stress,
were all upregulated 7 days after irradiation. Streeter PR
et al. [22] indicated that the activation of Flt-3 and G-CSF
receptors protected HSCs/HPCs from radiation damage.
These studies reveal that cytokine receptors play a vital
role in regulating and promoting hematopoiesis after ir-
radiation. The current study demonstrated that IL-3R ex-
pression in irradiated M-NFS-60 cells was significantly
upregulated 48 h after SVPII treatment. This upregulation
was further strengthened by addition of IL-3, indicating that
the proliferation promoting effect of SVPII on irradiated
cells is closely correlated with upregulation of IL-3R. Hence,
IL-3R is a potential therapeutic target for maintaining
hematopoietic function following irradiation.
Conclusion
Radiotherapy for cancer patient may lead to hematopoietic
failure. Recombinant cytokine treatment is the traditional
therapy for mitigating the inhibitory effect of irradiation on
hematopoiesis, but cytokine treatment also causes add-
itional adverse events. Thousands of potential agents that
confer radiation-resistance have been investigated. The pre-
vious investigation demonstrated the radioprotective effi-
cacy and tumor-inhibiting effect of peptides isolated from
the scorpion venom of Buthus Martti Karsch. In this paper,
we have demonstrated that the proliferation of irradiated
M-NFS-60 cells was significantly accelerated by scorpion
venom peptide II (SPVII) and induced 10-fold greater
overexpression of IL-3R in irradiated M-NFS-60 cells than
unirradiated cells. All these effects were further enhanced
by co-application of IL-3. Similarly, SPVII increased the
number of BM-MNC CFUs and this proliferative effect was
greater in the presence of SVPII plus IL-3. SPVII can also
alter the cell cycle fractions of M-NFS-60 cells (unirradiated
and irradiated). The significance of these results is that
SVPII possesses the hematopoietic growth factor (HGF)-
like effects on irradiated cells and the effect possibly
mediated by upregulation of IL-3R. The cytokines similar




The peptides SVPII and SVPIII (used only in
AlamarBlue™ assay) were isolated from the venom of
Buthus Martti Karsch as described [11]. Recombinant
human macrophage colony stimulating factor (rhM-
CSF) and recombinant mouse (rm) IL-3 were
purchased from PeproTech Co. AlamarBlue™ was pur-
chased from AbD Serotec (Great Britain), and mem-
brane protein isolation kits were from Bio-Rad. AnIL-3R antibody was purchased from Abcam Co.
Methyl cellulose for CFU assay was from Sigma-
Aldrich Co.
Cell line
The rhM-CSF-dependent cell line M-NFS-60 (CRL-1838™)
was purchased from ATCC Co. (USA).
Experimental procedures
M-NFS-60 cell culture and treatment groups
The M-NFS-60 cell line was cultured in PRMI 1640 culture
media supplemented with 10% fetal calf serum (FCS), 100
U/ml penicillin, 100 U/ml streptomycin, 5.958 g/L HEPES,
and 62 μg/L rhM-CSF. Cells were maintained at 37°C under
a 5% CO2 atmosphere. The media was changed every other
day. Cells were used for experiments in the exponential
growth phase. Unirradiated or 60Coγ-irradiated M-NFS-60
cells were treated with PBS (control), SVPII or SVPIII alone,
IL-3 alone, or SVP plus IL-3 for various durations.
Special cell culture methods M-NFS-60 cells were cul-
tured in serum-free media supplemented with 62 μg/L
rhM-CSF for 24 h (serum-free) or treated with 3 mg/L
SVP II (SVP II) or 10 μg/L IL-3 (IL-3). The control cells
were cultured 24 h in normal medium (24 h control).
After 24 h, the cell cycle was analyzed by FCM. After
cultured in serum-free media plus rhM-CSF for 24 h,
the cells were cultured in normal midium (mentioned
above) for an additional 72 h (serum-free) or treated
with SVPII 3 mg/L or IL-3 10 μg/L in the same media.
The control cells were cultured 96 h in normal medium
(96 h control). After 96 h, the cell cycle was analyzed by
FCM. Serum-free medium will lessen the influence fac-
tors on the cell cycle progression.
After irradiation by 60Coγ-ray M-NFS-60 cells were
cultured in PRMI 1640 culture media supplemented
with 10% FCS, 100 U/ml penicillin, 100 U/ml strepto-
mycin, 5.958 g/L HEPES, and 15.5 μg/L rhM-CSF (25%
of the normal M-CSF dose) for 48 h (irradiated control)
or treated with 3 mg/L SVPII or 10 μg/L IL-3 for 48 h.
Unirradiated cells were cultured 48 h in the same
medium were served as control. After 48 h, the cell cycle
was analyzed by FCM.
Cell irradiation
M-NFS-60 cells were irradiated by 60Coγ-ray at 5 Gy using
a Gammacell 3000 Elan installation (Nordion Intern. Inc.,
Canada). Proliferation and cell cycle progression were then
analyzed as described below.
Preparation of mouse BM-MNCs
All animal experiments in this study were approved by
the Institutional Animal Care and Use Committee of
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euthanized with CO2 and the femoral bones removed.
The femoral bone cavity was washed with low-sugar
DMEM medium to harvest bone marrow cells. The cells
in DMEM were then slowly added onto the surface of a
lymph cell isolation solution and centrifuged at 2000 rpm
for 20 min. The annular white layer consisting of mono-
cytes was collected, washed three times in PBS, and
resuspended in DMEM at the optimal concentration for
each experiment.
AlamarBlue™ cell viability assay
The AlamarBlue assay was used to measure the effect of
SVP on the proliferation of non-irradiated and irradiated M-
NFS-60 cells cultured in suspension. After irradiation or
sham treatment, M-NFS-60 cells were washed three times
in PRMI 1640 culture media, and the live cells counted
using Trypan Blue vital staining. The cell concentration was
adjusted to 5 × 104 cells/mL using PRMI 1640 culture media
containing 10% FCS and 62 μg/L rhM-CSF, and aliquoted at
80 μL/well in 96-well plates. After 24 h incubation at 37°C,
10 μL PBS (control), SVP (1, 3, or 4 mg/L), IL-3 (10 μg/L),
or SVP + IL-3 was added to each well. Each treatment was
performed in triplicate in the same 96-well plate. Following
control or drug treatment, 10 μL AlamarBlue™ was added to
each well and plates incubated at 37°C for 48 h. Optical
density (OD) values were measured and the cell prolifera-
tion rate calculated.
Colony forming unit (CFU) assay
A methyl cellulose half-solid colony formation method was
adopted to measure the number of bone marrow mono-
nuclear cell CFUs under different treatment conditions.
Treated BM-MNCs (1 × 106 cells/mL) were added into
methyl cellulose half-solid medium composed of DMEM,
0.8% methyl cellulose, 30% FCS, 2 mmol/L L-glutamine,
and the recombinant cytokines (10 μg/L IL-3 and 62 μg/L
rhM-CSF). The CFU number was counted under a micro-
scope after 7, 11, and 14 days of incubation at 37°C in a 5%
CO2 atmosphere. A mass consisting of more than 50 cells
was defined as 1 CFU.
Analysis of the cell cycle using FCM
The M-NFS-60 cells (non-irradiated or irradiated) were
treated as described. A 0.5 mL cell suspension (1 − 5 × 106/
mL) from each treatment group was combined with 2 ml
of cooled 70% ethanol and kept overnight at 4°C,
centrifuged at 1000 rpm/min, washed in PBS, and incu-
bated in the dark room at 4°C for 30 min with 50 μL
RNAse and 450 μL propidium iodide (PI) staining solution.
The proportion of cells in each phase of the cell cycle was
then determined by PI staining intensity using FACScalibur
flow cytometer (Becton Dickinson).Detection of IL-3R expression
Cell immunofluorescence Cultured M-NFS-60 cells on
glass slides were washed twice in PBS, fixed in −20°C
pre-cooled 100% methanol for 5 min, dried, and then
blocked in 5% BSA solution for 1 h at room temperature
or overnight in BSA at 4°C. The blocking solution was
removed and anti-IL-3R antibody (Abcam, USA) (1:200)
added for 1 h at 37°C or overnight at 4°C. After washing
in PBS, an FITC-labeled secondary antibody (F-0382;
Sigma) was applied at 1:500 in PBS. Slides were then
washed in PBS and sealed in glycerol. The expression of
IL-3R was detected by immunofluorescence under a
laser scanning confocal microscope (Leica DM1 4000B).
FCM analysis of IL-3R expression Cells were treated
as described, harvested, and the concentration of M-
NFS-60 cells adjusted to between 5 × 106 and 1 × 107
cells/mL in PRMI 1640 culture medium. To this cell
suspension were added a monoclonal antibody (5–50
μL) and 50 μL inactivated rabbit serum. Cell suspensions
were incubated at 4°C for 30 min, washed in PBS, and
centrifuged. The supernatants were removed, and the
pellets treated with 50 μL of a FITC-conjugated goat
anti-mouse antibody, shaken at 4°C for 30 min, washed
twice in PBS, centrifuged, and fixed as described in sec-
tion 3.7.1.
Western blotting Membrane proteins from the differ-
ent treatment groups were extracted using a Bio-Rad
membrane protein extract kit. Total protein concentra-
tions were measured by the Lowry assay and extracts
run on 12% SDS-PAGE gels. Separated proteins were
electrotransferred to polyvinyl membranes. Membranes
were probed with an IL-3R antibody and visualized using
chemiluminescence.
Statistical analysis
The data are expressed as mean ± SD. SPSS statistical soft-
ware was used to perform chi-square analysis. P < 0.05 was
considered statistically significant.
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